Jan 29, 2025 · Right heart size differs between men and women with PAH: Study. Men with pulmonary arterial hypertension (PAH) have a larger right heart size and worse survival rates than women, independent of body size and functional status, a study reports.

5 days ago · The data show the benefits of seralutinib treatment over nearly 1.5 years, according to the company. The results were presented by Gossamer at the Pulmonary Vascular Research Institute 2025 Annual Congress, which took place Jan. 29-Feb. 1 in Rio de Janeiro, per a press release from the biopharmaceutical. “These data underscore seralutinib’s potential to transform the PAH treatment paradigm ...

Jul 8, 2019 · An estimated right ventricular systolic pressure (eRVSP) — a measure of the pressure inside the artery that supplies blood to the lungs (pulmonary artery) — greater than 30.0 mmHg is related to an increased risk of mortality in patients with pulmonary hypertension (PH), according to a new Australian study.

Jan 31, 2025 · The participants in HYPERION (NCT04811092) can now all choose to be treated with Winrevair as part of the open-label extension study SOTERIA (NCT04796337), according to the developer.. The decision to end the trial early was based on new positive data from another Phase 3 trial of Winrevair — early results that Merck said made continuing HYPERION unnecessary, and also not helpful for its ...

Dec 16, 2024 · An oxygen-sensing protein called hypoxia-inducible factor-1alpha, or HIF-1alpha, may contribute to worsening pulmonary arterial hypertension (PAH) and is a possible therapeutic target for people with this rare type of pulmonary hypertension, a study by …

Jan 17, 2025 · The dosing regimen for Winrevair (sotatercept-csrk) is optimal for balancing efficacy and safety in adults with pulmonary arterial hypertension (PAH), an analysis of clinical trial data shows. This regimen is “well-justified based on the totality of the observed safety and efficacy data from Phase ...

Dec 20, 2024 · In PAH, high blood pressure in the blood vessels that carry blood from the heart to the lungs results in symptoms like shortness of breath, fatigue, and chest pain. The disease can make even simple activities, like walking or climbing stairs, increasingly difficult and negatively impacts patients’ quality of life.

Pulmonary Hypertension News is a digital platform intended to provide the pulmonary hypertension (PH) community with the most recent news and information on PH, as well as first-hand community perspectives from our patient and caregiver columnists.. All articles on Pulmonary Hypertension News are original content produced by in-house writers and editors.

Living with a chronic disease like pulmonary hypertension (PH) can be challenging. It can affect a patient’s ability to accomplish daily tasks, as well as affect their quality of life.

Oct 2, 2024 · Outcomes of PAH with CS1. The Phase 2 CS1-003 trial (NCT05224531) was designed to explore the safety, tolerability, and preliminary efficacy of CS1 on top of standard of care in 25 adults with PAH who were randomly assigned to receive one of three daily oral doses — 480 mg, 960 mg, or 1,920 mg — for 12 weeks, or about three months. The treatment was safe and well tolerated, meeting the ...